{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 39,
        "end": 48
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 51,
        "end": 55
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 180,
        "end": 184
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 180,
        "end": 200
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 292,
        "end": 300
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "12150448_4",
  "text": "We pre-selected patients with advanced HER-2/neu ( HER2 ) overexpressing breast and ovarian cancers for enrolment into a phase I trial designed to evaluate the immunogenicity of a HER2 peptide vaccine based on the patient 's immune competence as assessed by DTH skin testing to common recall antigens ( Multitest CMI , Institut Merieux , Lyon , France ) ."
}
